Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | ANDROMEDA: daratumumab for AL amyloidosis

Angela Dispenzieri • 31 May 2020
Amyloidosis Rare Diseases Antibodies Bortezomib Cyclophosphamide Daratumumab Dexamethasone
ANDROMEDA

Angela Dispenzieri, MD, of the Mayo Clinic College of Medicine, Rochester, MN, discusses the use of daratumumab for amyloid light-chain (AL) amyloidosis and clinical trials evaluating its use. Specifically highlighted is the ANDROMEDA study (NCT03201965), as well as prospective trials in the relapsed/refractory setting. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Angela Dispenzieri

1:53
Unmet needs in amyloidosis: early diagnosis, treating relapsed disease & progression criteria
Angela Dispenzieri • 6 Sep 2023
2:30
Emerging AL amyloidosis treatments: immunotherapies & targeting amyloid plaque deposits
Angela Dispenzieri • 6 Sep 2023
1:42
The current SOC in AL amyloidosis: dara-CyBorD & considerations for patients with relapsed disease
Angela Dispenzieri • 6 Sep 2023
1:57
Rationale behind the watch and wait strategy in smoldering myeloma
Angela Dispenzieri • 6 Sep 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals